Earlier this month, the U.S. Food and Drug Administration approved Johnson & Johnson's (NYSE: JNJ) Invega Hafyera, the first and only twice-yearly injectable drug to treat schizophrenia. This FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results